Global Infectious Disease Therapeutics Market

Infectious Disease Therapeutics Market Size, Share, Growth Analysis, By Mode of treatment(Vaccines and drugs), By Target organism (Antiviral, antifungal, antibacterial, anti-parasite), By Infection type(Parasitic, viral, fungal, bacterial), By Distribution channel(Hospitals, clinics, and others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2030 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 119 | Figures: 77

Infectious Disease Therapeutics Market Insights

Infectious Disease Therapeutics Market size was valued at USD 115 billion in 2019 and is poised to grow from USD 119.86 billion in 2023 to USD 166.97 billion by 2031, growing at a CAGR of 4.23% in the forecast period (2024-2031).

Infectious disease is a major cause of significant pressure in the global healthcare industry. These diseases, also known as transmissible or communicable diseases, are caused by a variety of infectious agents such as viruses, viroids, and bacteria. The introduction of various technologically advanced diagnosis and treatment options, as well as advancements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases. However, the rise and re-emergence of infectious diseases have a significant impact on the global population's health outcomes. The infectious disease therapeutics market is anticipated to grow significantly over the forecast period, attributed to rising infectious disease occurrence, increased awareness about early infectious disease diagnosis, and increased research funding activities by various private and government organisations. However, the high cost of treating infectious diseases with highly developed medicines severely restricts market growth by putting additional strain on people's disposable income. The market's increasing demand for generic drugs has also hampered the growth of labelled drugs that treat infectious diseases.

US Infectious Disease Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Infectious Disease Therapeutics Market size was valued at USD 115 billion in 2019 and is poised to grow from USD 119.86 billion in 2023 to USD 166.97 billion by 2031, growing at a CAGR of 4.23% in the forecast period (2024-2031).

Global infectious disease therapeutics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'GlaxoSmithKline plc', 'Merck & Co.', 'Pfizer Inc.', 'Roche Holding AG', 'Novartis AG', 'Sanofi S.A.', 'Johnson & Johnson', 'AstraZeneca plc', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol-Myers Squibb Company', 'Eli Lilly and Company', 'Gilead Sciences, Inc.', 'Bayer AG', 'Novo Nordisk A/S', 'Takeda Pharmaceutical Co. Ltd.', 'Biogen Inc.', 'Boehringer Ingelheim GmbH', 'Allergan plc', 'Celgene Corporation'

Increased spending to enhance the penetration rate of infectious disease treatments, rising strategies to raise awareness about treatments and diagnosis of these conditions, and increased clinical trial research for the development of new drugs may drive the growth of global infectious disease therapeutics market over the forecast period.

Increasing prevalence of malaria disease in developing and underdeveloped countries including India, Africa, and other Southeast Asian countries, as well as increased research and development activities by key manufacturers and health care organisations, are all contributing to market development.

North America held the largest global infectious disease therapeutics market share in 2021 due to the region's growing rate of infectious diseases. This region's large geriatric population has emerged as a significant growth factor for the market during the forecast period. People's increased disposable income has also become an important growth factor. The government's provision of advanced health-care facilities in the form of reimbursement policies has greatly aided market growth. Moreover, the existence of key manufacturers in the United States, as well as an increase in clinical trials for the introduction of new treatment drugs, are estimated to generate to this region's large market share.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Infectious Disease Therapeutics Market

Report ID: SQMIG35J2030

$5,300
BUY NOW GET FREE SAMPLE